National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 72078 [2015-29380]
Download as PDF
<![CDATA[
72078
Federal Register / Vol. 80, No. 222 / Wednesday, November 18, 2015 / Notices
Control and Population Sciences, 9609
Medical Center Drive, 3E438, MSC
9764, Rockville, MD, 20850 or call nontoll-free number 240–276–6806 or Email
your request, including your address to:
janet.demoor@nih.gov. Formal requests
for additional plans and instruments
must be requested in writing.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Proposed Collection: The National
Physician Survey of Precision Medicine
in Cancer Treatment 0925–NEW,
National Cancer Institute (NCI),
National Institutes of Health (NIH).
Need and Use of Information
Collection: The purpose of this study is
to investigate the current practice of
Non-respondents will be invited to
complete a follow-back survey to share
their reasons for not participating. The
study findings will inform NCI of
relevant issues and concerns relating to
the application of precision medicine to
current and future cancer treatment
patterns and practice. This information
will also inform the development of
new funding initiatives to optimize the
use of precision medicine in cancer
treatment. Additionally, information
collected as part of this survey will be
used to develop physician educational
materials to address barriers to precision
medicine in cancer care delivery.
OMB approval is requested for 2
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
261.
precision medicine in cancer treatment
among medical oncologists in the U.S.
This is a nationally representative
survey designed to assess oncologists’
current and potential use of genomic
testing, to inform the development of
interventions to facilitate optimal use of
genomic testing and to improve patientphysician discussions of the risks,
possible benefits, and uncertainties
surrounding the use of these tests.
Current knowledge of this topic is
limited as there are no nationallyrepresentative studies on this topic to
date. There are only two non-federal
studies two that have examined
physicians’ knowledge and attitudes
regarding somatic genetic and genomic
testing. The survey will be administered
by mail and web to approximately 1,630
oncology physicians across the U.S.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total annual
burden hour
Form name
Type of respondent
Precision Medicine Survey—Pilot
Study.
Precision Medicine Survey—Full
Study.
Follow-back Survey ...........................
Oncology Physicians ........................
175
1
20/60
58
Oncology Physicians ........................
600
1
20/60
200
Oncology Physicians ........................
40
1
5/60
3
Dated: October 28, 2015.
Karla Bailey,
Project Clearance Liaison, NCI, NIH.
[FR Doc. 2015–29382 Filed 11–17–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
asabaliauskas on DSK5VPTVN1PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Sep<11>2014
18:50 Nov 17, 2015
Jkt 238001
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Innovation for HIV Vaccine
Discovery (R01).
Date: December 10–11, 2015.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
3G61, 5601 Fishers Lane, Rockville, MD
20892 (Telephone Conference Call).
Contact Person: Jane K. Battles, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room # 3F30B, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20852–9823, (240) 669–5029,
battlesja@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 12, 2015.
Natasha Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–29380 Filed 11–17–15; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse
Amended; Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute on
Drug Abuse Special Emphasis Panel,
November 13, 2015, 01:00 p.m. to
November 13, 2015, 05:00 p.m.,
National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD, 20852 which
was published in the Federal Register
on October 22, 2015, 80 FR 64428.
The date of the meeting was changed
to December 1, 2015. The meeting is
closed to the public.
Dated: November 12, 2015.
Natasha Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–29379 Filed 11–17–15; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
PO 00000
Frm 00039
Fmt 4703
Sfmt 9990
E:\FR\FM\18NON1.SGM
18NON1
]]>Agencies
[Federal Register Volume 80, Number 222 (Wednesday, November 18, 2015)]
[Notices]
[Page 72078]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-29380]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Innovation for HIV Vaccine
Discovery (R01).
Date: December 10-11, 2015.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Room 3G61, 5601 Fishers
Lane, Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Jane K. Battles, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, Room # 3F30B, National Institutes of Health/NIAID, 5601
Fishers Lane, MSC 9823, Bethesda, MD 20852-9823, (240) 669-5029,
battlesja@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: November 12, 2015.
Natasha Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-29380 Filed 11-17-15; 8:45 am]
BILLING CODE 4140-01-P
